What are the side effects of Sotorasib?

In the CodeBreaK 100 clinical trial, the safety of Sotorasib (Sotorasib) was evaluated in patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer. 50% of patients treated with sotorasib experienced serious adverse reactions. Serious adverse reactions included pneumonitis, hepatotoxicity, and diarrhea in ≥2% of patients. Fatal adverse reactions occurred in 3.4% of patients treated with sotoraxib due to respiratory failure, pneumonia, cardiac arrest, heart failure, gastric ulcer, and pneumonia.

Five percent of patients had sotorasiib dose reductions due to adverse reactions, including alanine aminotransferase increases and aspartate aminotransferase increases. 34% of patients discontinued sotorasiib dose due to adverse reactions, including hepatotoxicity, diarrhea, musculoskeletal pain, nausea, and pneumonitis. Nine percent of patients permanently discontinued sotoraxib due to hepatotoxicity. The most common laboratory abnormalities (≥25%) were lymphopenia, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, decreased calcium, increased alkaline phosphatase, increased urinary protein, and decreased sodium.

SotoracibThe original drug has not yet been launched in China, so it is not covered by medical insurance. Domestic patients cannot yet purchase this drug. The price of Hong Kong original research versionsotorasibuSpecifications120mg*240 tablets is about RMB 80,000, and the European original research version 120mg*240 tablets is priced at about RMB 44,040 (the price may fluctuate due to the exchange rate), which is relatively expensive. There are also cheaper generic drugs for sale in other countries. The specifications of the Laos Element Pharmaceutical Factory are 120mg*56 tablets and the price is around 4800 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The ingredients of foreign generic drugs are basically the same as the original drugs.